drugset / Trial / NCT04627363
HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama
Phase 2
Unknown
30 enrolled
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm clinical study to preliminarily observe and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin synchronous combined with Bevacizumab and Toripalimab as the first-line therapy for advanced HCC.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-06-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |